drugset / Trial / NCT00100152

A Notch Signalling Pathway Inhibitor for Patients With T-cell Acute Lymphoblastic Leukemia/Lymphoma (ALL)(0752-013)

NCT00100152

Phase 1 Terminated 50 enrolled Merck Sharp & Dohme LLC
Non-randomizedSingle-groupOpen-labelTreatment

Summary

A Notch signalling pathway inhibitor study in pediatric and adult patients with relapsed (worsening) or refractory (not responding to treatment) T-cell acute lymphoblastic leukemia/lymphoma (T-ALL).

Timeline

Start
2005-02
Primary completion
2006-09
Completion
2006-10

Drugs

EvaluationDrugModalityDoseRoute
Subject MK-0752 Small molecule